The stock of Adc Therapeutics SA (ADCT) has gone down by -3.99% for the week, with a -5.15% drop in the past month and a -22.91% drop in the past quarter. The volatility ratio for the week is 6.64%, and the volatility levels for the past 30 days are 7.38% for ADCT. The simple moving average for the past 20 days is -1.90% for ADCT’s stock, with a -42.79% simple moving average for the past 200 days.
Is It Worth Investing in Adc Therapeutics SA (NYSE: ADCT) Right Now?
Moreover, the 36-month beta value for ADCT is 1.53. Analysts have varying opinions on the stock, with 4 analysts rating it as a “buy,” 2 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for ADCT is 75.93M and currently, short sellers hold a 6.42% of that float. On February 28, 2025, ADCT’s average trading volume was 929.68K shares.
ADCT) stock’s latest price update
The stock of Adc Therapeutics SA (NYSE: ADCT) has decreased by -0.95 when compared to last closing price of 1.58. Despite this, the company has experienced a -3.99% fall in its stock price over the last five trading sessions. prnewswire.com reported 2025-02-03 that LAUSANNE, Switzerland, Feb. 3, 2025 /PRNewswire/ — ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that the Company has made grants of options to purchase an aggregate of 26,800 of the Company’s common shares to three new employees on February 3, 2025 (each, a “Grant”). The Grants were offered as material inducement to the employees’ employment.
Analysts’ Opinion of ADCT
Many brokerage firms have already submitted their reports for ADCT stocks, with Stephens repeating the rating for ADCT by listing it as a “Overweight.” The predicted price for ADCT in the upcoming period, according to Stephens is $6 based on the research report published on November 08, 2024 of the previous year 2024.
Guggenheim gave a rating of “Buy” to ADCT, setting the target price at $11 in the report published on March 28th of the previous year.
ADCT Trading at -11.48% from the 50-Day Moving Average
After a stumble in the market that brought ADCT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -70.91% of loss for the given period.
Volatility was left at 7.38%, however, over the last 30 days, the volatility rate increased by 6.64%, as shares sank -9.30% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -17.46% lower at present.
During the last 5 trading sessions, ADCT fell by -4.29%, which changed the moving average for the period of 200-days by -63.72% in comparison to the 20-day moving average, which settled at $1.5950. In addition, Adc Therapeutics SA saw -21.36% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ADCT starting from Redmile Group, LLC, who purchase 100,000 shares at the price of $3.04 back on Dec 11 ’24. After this action, Redmile Group, LLC now owns 15,666,731 shares of Adc Therapeutics SA, valued at $304,500 using the latest closing price.
Redmile Group, LLC, the 10% Owner of Adc Therapeutics SA, purchase 100,000 shares at $3.04 during a trade that took place back on Dec 11 ’24, which means that Redmile Group, LLC is holding 13,145,712 shares at $304,500 based on the most recent closing price.
Stock Fundamentals for ADCT
Current profitability levels for the company are sitting at:
- -1.97 for the present operating margin
- 0.89 for the gross margin
The net margin for Adc Therapeutics SA stands at -3.02. The total capital return value is set at -0.49.
Based on Adc Therapeutics SA (ADCT), the company’s capital structure generated 2.08 points at debt to capital in total, while cash flow to debt ratio is standing at -0.4. The debt to equity ratio resting at -1.93. The interest coverage ratio of the stock is -2.7.
Currently, EBITDA for the company is -146.76 million with net debt to EBITDA at -0.51. When we switch over and look at the enterprise to sales, we see a ratio of 3.0. The receivables turnover for the company is 2.92for trailing twelve months and the total asset turnover is 0.2. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.92.
Conclusion
To wrap up, the performance of Adc Therapeutics SA (ADCT) has been bad in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
